MoonLake Immunotherapeutics (MLTX) Income towards Parent Company (2021 - 2026)

MoonLake Immunotherapeutics' Income towards Parent Company history runs 6 years deep, the most recent figure standing at -$69.7 million for Q1 2026.

• In Q1 2026, Income towards Parent Company fell 71.87% year-over-year to -$69.7 million; the TTM figure through Mar 2026 stood at -$259.5 million (down 75.52% YoY), while the FY2025 annual figure was -$230.3 million, down 89.96% from the prior year.
• Income towards Parent Company was -$69.7 million for Q1 2026 at MoonLake Immunotherapeutics, down from -$63.0 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$7.9 million in Q4 2023 to a low of -$70.7 million in Q3 2025.
• Historically, Income towards Parent Company has averaged -$31.2 million across 5 years, with a median of -$17.4 million in 2022.
• Biggest YoY gain for Income towards Parent Company was 69.3% in 2022; the steepest drop was 20715.22% in 2022.
• A 5-year view of Income towards Parent Company shows it stood at -$16.5 million in 2022, then jumped by 52.11% to -$7.9 million in 2023, then sank by 488.23% to -$46.4 million in 2024, then slumped by 35.83% to -$63.0 million in 2025, then retreated by 10.61% to -$69.7 million in 2026.
• The last three Income towards Parent Company figures came in at -$69.7 million (Q1 2026), -$63.0 million (Q4 2025), and -$70.7 million (Q3 2025), per Business Quant data.